Background: Studies have demonstrated that cholesterol variability is an independent predictor of cerebrovascular and cardiovascular events. Objective: This study aimed to investigate the association of visit-to-visit variability in total cholesterol (TC) with kidney decline in a Chinese community-based population. Methods: We assessed intraindividual variability in TC among 6,465 hypertensive participants and correlated the results with endpoints. TC variability was measured using standard deviation (SD), average successive variability (ASV), coefficient of variation (CV), and variability independent of the mean (VIM). The endpoint of this study was progression of renal function decline defined as a decrease in estimated glomerular filtration rate (eGFR) ≥30% and to a level < 60 mL/min/1.73 m 2 during follow-up if the baseline eGFR was ≥60 mL/min/1.73 m 2 , or a decrease in eGFR ≥50% during follow up if the baseline eGFR was < 60 mL/min/1.73 m 2 . Results: After a median follow-up of 27 months, 13.5% (n = 877) of the participants experienced progression of renal function decline. In the multivariable-adjusted Cox model, each 1-SD increase in TC variability (by SD) increased the risk of renal function decline by 11% (HR = 1.11; 95% CI 1.034-1.197; p = 0.004); this was independent of the baseline eGFR, mean follow-up TC levels, and the lipid-lowering therapy. Similar results were found for the 3 other measures of variability, i.e., ASV, CV, and VIM. Conclusion: In subjects with hypertension, visit-to-visit variability in TC is an independent predictor of renal function decline.
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from the questionnaire by community doctors. The presence of diabetes mellitus (DM) was defined according to the following criteria: (1) fasting glucose level of 7.0 mmol/L and (2) use of hypoglycemic agents to control blood glucose levels. Cerebrovascular disease was defined as a history of cerebrovascular accidents including cerebral bleeding and infarction. Coronary artery disease was defined as a history of typical angina with a positive stress test, an old myocardial infarction, or having undergone coronary artery bypass surgery or angioplasty. Use of antihypertensive agents (including diuretics, β-blockers, angiotensin-converting enzyme inhibitor [ACEi] , angiotensin II receptor blockers [ARB] , and calcium channel blockers [CCB] ), lipid-lowering agents (statins or nonstatin drugs), and hypoglycemic agents (insulin or oral antidiabetic drugs) were also captured. Blood pressure was measured as the mean of 2 readings made in a seated position using an OMRON HBP1100u semiautomatic oscillometric recorder after resting for 5 min. BMI was calculated as the subject's weight in kilograms divided by the square of the subject's height in meters. Blood samples were captured after an overnight fast for the measurement of serum glucose, hemoglobin A1c (HbA1c), serum creatinine (Scr), TC, LDL-C, and high-density lipoprotein cholesterol (HDL-C) levels, among others.
TC Variability
TC variability was defined as the variation in TC values between health examinations. The following 4 measurements of variability were used: (1) the standard deviation (SD) of TC levels; (2) the average successive variability (ASV), defined as the average absolute difference between successive values; (3) coefficient of variation (CV); and (4) variability independent of the mean (VIM).VIM was calculated as 100× SD/mean β , where β is the regression coefficient, using the natural logarithm of SD divided by the natural logarithm of the mean [13] . The number of TC measurements per subject ranged from 3 to 6.
Study Outcomes and Follow-Up
Scr was captured at each health examination, and the eGFR was calculated with an equation developed by adaptation of the Modification of Diet in Renal Disease equation as follows: eGFR = 175 Scr −1.234 • age -0.179 (if female, 0.79) [23] . The endpoint of this study was the progression of renal function decline, defined as a decrease in eGFR ≥30% and to a level < 60 mL/min/1.73 m 2 during follow-up if the baseline eGFR was ≥60 mL/min/1.73 m 2 , or a decrease in eGFR ≥50% during follow-up if the baseline eGFR was < 60 mL/min/1.73 m 2 (including those who had developed ESRD [eGFR < 15 mL/min/1.73 m 2 ] and a need for dialysis) [24] . Every enrollee was followed up annually and underwent health examinations, and at each visit vital signs and concurrent medication information were recorded. In addition, physical examinations and blood pressure measurements were performed and laboratory specimens, including TC, Scr, and fasting blood glucose (FBG) measurements were collected.
Statistical Analysis
In this study, all of the data analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). Continuous data are described as means ± SD, while dichotomous variables are expressed as percentages. Student's t test and the χ 2 test were performed for continuous and discrete variables, respectively. The univariate Cox proportional hazards regression model illustrates the variable which had a significant difference with the occurrence of the outcome. In addition, we used a univariate linear regression model to identify predictors of TC variability. Then, the multivariable-adjusted Cox proportional hazards model was applied to calculate the HR for outcome per 1-SD increase in variability in TC. Model 1 was adjusted for age, sex, BMI, smoking, regular exercise, and DM. Model 2 was further adjusted for systolic blood pressure (SBP), FBG, use of antihypertensive agents, and mean follow-up TC, and model 3 was further adjusted for use of lipid-lowering agents and eGFR. The endpoint-free probability according to the quartiles of TC variability was calculated using Kaplan-Meier curves, and the log-rank test was used to analyze differences between the participants above the third quartile (IQR, P75) and below the third quartile. The potential effect modification by sex, age, obesity (defined as a BMI ≥25), a low eGFR (defined as an eGFR of 60 mL/min/1.73 m 2 ), DM, dyslipidemia medicine, and systolic pressure was evaluated through subgroup analysis and interaction testing using a likelihood ratio test. We also performed a stratified analysis to unmask medication interaction with the relationship between cholesterol variability and renal function decline. A time-dependent Cox regression was performed in order to assess whether the risk of renal function decline would vary with time. In each statistical test, p < 0.05 (2-sided) was considered statistically significant. 
Results

Characteristics of the Study Population
The baseline demographics and clinical characteristics of the overall study population are shown in Table 1 . The total number of participants was 6,465, and after a median followup of 27 months 13.5% of the participants had progression of renal function decline (according to the criteria mentioned above Data are expressed as the means ± SD or numbers (%). The total number of subjects was 6,465. years and the population was 44.9% male. All of the participants were adults with hypertension, 16.4% of them had DM, 1.5% of them had a history of coronary heart disease, and 2% had a history of cerebrovascular disease. The baseline TC and mean follow-up TC values for the study population were 198.70 ± 42.63 and 205.80 ± 37.45 mg/dL, respectively. Nevertheless, only 6.2% of the subjects were taking lipid-lowering drugs at baseline. Table  2 shows the comparison of baseline characteristics between participants with progression and no progression of kidney function decline. Patients in the progression group were older (p < 0.001) and more likely to be female and have a history of coronary heart disease (p = 0.003), as well as higher SBP (p < 0.001), diastolic blood pressure (DBP) (p = 0.001), and triglyceride (p = 0.005) values and lower eGFR (p < 0.001) values than those in the no-progression group. In addition, patients with renal function decline were more frequently treated with ACEi/ARB, β-blockers, and CCB, whereas the same subjects were less frequently treated with statins and oral hypoglycemic agents. Baseline TC levels were similar for the progression and no-progression groups (p = 0.789), while the mean follow-up TC levels were higher in the progression group (p = 0.017). All of the measures of visit-to-visit TC variability (including CV, SD, ASV, and VIM) for the progression group were significantly higher than for the no-progression group (p < 0.001).
Determinants of Renal Function Decline
The relationship between clinical parameters and the endpoint was assessed by univariate Cox regression analysis, as shown in Table 3 . The risk of a decline in renal function was significantly higher among participants who were female (HR = 1.5; 95% CI 1.31-1.73) and older (HR = 1.03; 95% CI 1.02-1.03), had a history of diabetes (HR = 1.30; 95% CI 1.09-1.56), and had a higher TC variability (described by SD [HR = 
1.22])
. Not unexpectedly, the use of antihypertensive agents, especially ACEi/ARB, slowed the progression of kidney function decline, though it did not reach statistical significance (HR = 0.97; p = 0.606).
Predictors of Visit-to-Visit TC Variability
Simple linear regression analysis of TC variability is shown in Table 4 . TC variability was significantly associated with sex, BMI, a history of DM, and lipid-lowering therapy. Moreover, the higher the SBP and FBG values were, the higher the TC variability was, while there was a negative correlation between the baseline eGFR and TC variability. No correlations between visit-to-visit TC variability and age, drinking, or uric acid were observed. Figure 2 is a forest plot of the HR of TC variability using 4 different measures of variability with and without adjustment for demographic characteristics and other confounding factors. In the unadjusted model, visit-to-visit variability in TC was associated with a significant increase in the risk of renal function decline. For every 1-SD increase in TC variability (as measured by SD), the risk of renal function decline increased by 14% (HR = 1.14; 95% CI 1.07-1.22; p < 0.001). Furthermore, visit-to-visit TC variability as measured by SD was an independent predictor of progression of renal function decline even after adjusting for age, sex, BMI, smoking, regular exercise, DM (HR = 1.13; 95% CI 1.058-1.211; p < 0.001). After further controlling for other confounding factors, including SBP, FBG, use of antihypertensive agents, mean follow-up TC, use of lipid-lowering agents, and baseline eGFR, the association between cholesterol variability and the endpoint remained significant (HR = 1.11; 95% CI 1.034-1.197; p = 0.004). TC variability as measured by ASV, CV, or VIM was also an independent predictor of kidney function decline, even after full multivariable adjustment. Furthermore, the incidence rate of outcomes was higher in the group with TC variability above the third quartile (IQR, P75) compared to the group with TC variability below the P75, indicating that the higher the TC variability was, the faster the kidney function deterioration occurred (Fig. 3) . 
Visit-to-Visit TC Variability and Progression of Renal Function
Subgroup Analyses
Stratified analyses were performed to further assess the relationship between TC variability and renal function decline in various subgroups. None of the variables, including age (60 vs. 60 years; p for interaction = 0.4775), sex (p for interaction = 0.2888), obesity (p for interaction = 0.2608), DM (p for interaction = 0.6578), dyslipidemia medicine (p for interaction = 0.9431), low eGFR (p for interaction = 0.0596), or blood pressure levels (p for interaction = 0.9281) significantly modified the association between TC variability (by SD) and the endpoint. These findings were consistent when using other indices of variability, including ASV, CV, and VIM (Fig. 4) . To account for the possible influence of medications on the relationship between variability in TC and the endpoint, we performed a subgroup analysis based on different drug types. The associations between TC variability and renal function decline were consistent across various drug subgroups. There were no significant interactions in any of the 11 predefined subgroups (p > 0.10 for all comparisons). These findings were consistent no matter which indices of variability were used (Fig. 5) .
Sensitivity Analyses
The results were similar in the sensitivity analyses that used TC variability as a timedependent covariate. For every 1-SD increase in TC variability (as measured by SD), the risk of renal function decline increased by 15% (p < 0.001). After controlling for multiple variables, the risk increased by 11% (online suppl. Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000501367). 
Discussion
In the present study, we enrolled 6,465 hypertensive patients in a community of China, most of whom had a normal kidney function at baseline. We demonstrated that TC variability was an independent predictor of progression of renal function decline, even after multivariable adjustment for potential confounding factors, including blood pressure level, baseline eGFR, and lipid-lowering therapy. In the full adjustment model, for every 1-SD increase in TC variability (as measured by SD) the risk of the endpoint increased by 11%. Of particular importance, the results obtained using different indices of TC variability were consistent. To the best of our knowledge, this analysis is the first to demonstrate the association between lipid variability and renal function decline in hypertensive patients and add to the evidence that visit-to-visit variability in TC is a predictor of cardiovascular events. Intraindividual variability in biological parameters such as BP variability and heart rate variability has been recognized as a new biometric. Studies have shown that short-or longterm visit-to-visit variability in BP portends a worsening prognosis and that a greater BP variability is associated with an increased risk of cardiovascular events, stroke, and death in those with hypertension [25, 26] . A 15-year retrospective cohort study conducted by Chia et al. [19] showed that variability in blood pressure accelerates the deterioration of kidney function and contributes to the progression of CKD independently of the blood pressure [19] . Similarly to BP, visit-to-visit variability in cholesterol portends a worsening prognosis; however, the data on cholesterol variability and prognosis are limited. Evidence from the Treating to New Targets trial suggested that a greater LDL-C variability was a strong predictor of coronary events, myocardial infarction, stroke, and death in patients with known coronary artery disease [13] . In the IDEAL trial, which enrolled patients with a previous myocardial infarction, showed that variability in LDL-C was closely related to adverse outcomes including coronary events, myocardial infarction, stroke, and death [26] . The Prospective Study of Pravastatin in the Elderly at Risk showed that a higher LDL-C variability was closely related to a lower neurocognitive performance, a lower cerebral blood flow, and greater white matter hyperintensity on brain magnetic resonance imaging [14] . The relationship between cholesterol vari- ability and cardiovascular events now seems established. Nevertheless, the data available in the literature on the effects of lipid variability on renal dysfunction is scarce. Analysis form a national population-based study in Korea demonstrated that TC variability was a determinant of ESRD independently of preexisting CKD [27] . Our results add supportive data on the relevance of TC variability and kidney disease and extend the previous study by showing that, among hypertensive patients (with or without a low eGFR), those with a high TC variability were more likely to have progression of renal function decline. It is widely accepted that hypertension and DM are essential to accelerate the deterioration of renal function. In our study, after blood pressures, a history of DM, use of antihypertensive drugs, FBG, and other confounders had been fully adjusted, TC variability was still linked to kidney function decline. It is worth noting that this is in contrast to data from prior research, in which lipidlowering treatments have a protective effect against the progression of renal function decline [16, 17] . However, the results we obtained are relevant, albeit with a lack of significance (p = 0.457). A possible explanation for this finding is that very few participants used the lipidlowering agents at baseline (n = 399, 6.2%) and most of the patients started lipid-lowering therapy later on. Another explanation for the observed discrepancy is poor medication compliance; in China, especially in the Chinese community, it is common for patients to stop taking pills at will. Moreover, lipid-lowering therapy might be related to the high TC variability, which has been shown in the simple linear regression analysis of TC variability from our data as well. Also, it is likely that the beneficial effects of the use of statins is mitigated by the impact of the high TC variability.
Moreover, in the univariate Cox regression analyses, SBP and FBG at baseline had little effect on the progression of renal function decline. However, a history of DM is a remarkable risk factor for renal function decline. One explanation could account for all these oddities. All of the participants had hypertension, and some patients took antihypertensives and antidiabetic agents at baseline. Then, some of them stopped taking these pills at will and those who were not using blood pressure-lowering medications or hypoglycemic drug at baseline may have started the treatment then. As a result, the association between SBP (or FBG) at baseline and renal function deterioration is weak.
The biological mechanisms underlying TC variability and the correlation to the progression of kidney function decline warrants further investigation, and several explanations could be suggested. Hypertension, endothelial dysfunction, inflammation, and oxidative stress, which are the same pathophysiological factors that lead to atherosclerosis, are believed to be the principal causal mechanisms of kidney dysfunction [28, 29] . Recent studies suggest that a higher cholesterol variability is associated with a lower cerebral blood flow but also with a greater white matter hyperintensity load, which has been linked to endothelial dysfunction [14] . Therefore, one pathway could be through endothelial dysfunction, which plays a vital role in renal function decline [30, 31] . Lipid deposition and the appearance of foam cells in glomeruli accompany kidney injury in models of hyperlipidemia [29, 32] . Fluctuations in blood cholesterol may contribute to the renal function decline directly, owing to the instability of vascular wall led by the fluctuations in the composition of lipid deposits [27] . It is noteworthy that, although TC variability is a predominant risk factor for renal function decline, the potential for causality reversal needs to be noted. It is hard to exclude the possibility that renal disease increases lipid variability since impaired kidney function exhibits increased concentrations of lipids and a required LDL-C receptor deficiency [33] . Moreover, patients who have a faster renal function decline might have a greater TC variability in virtue of their lipid metabolism changes.
There are some distinguishing points of this study. First, it has a relatively large size, i.e., more than 6,000 hypertensive patients, which is large enough to show the association between TC variability and progression of kidney function decline in patients with hypertension. Second, it is the first study to evaluate the influence of cholesterol variability on renal function decline in hypertensive residents of a Chinese community. Finally, we collected the eGFR and assessed the renal function at each visit; frequent renal function assays allows a more accurate assessment of changes in kidney function over time. Several limitations of the current analysis warrant consideration. First of all, our results were based on post hoc analyses, and causality cannot be determined. However, in order to minimize the possible effects of reverse causality, subjects with an eGFR < 15 mL/min/1.73 m 2 at baseline were excluded, and the subgroup analyses were conducted in patients with a low eGFR or without a low eGFR. Second, we failed to provide baseline microalbuminuria or urinary albumin data, which are closely associated with kidney function decline. Third, it is the lack of plausible mechanisms whereby the variability of cholesterol levels in people not on lipid medication might bear a causative relationship with renal decline. Lastly, the participants were limited to hypertensive residents in a Chinese community; it is uncertain whether these findings can be extrapolated to other groups. 
Conclusion
Visit-to-visit variability in TC is important in determining the progression of kidney function deterioration in patients with hypertension. Patients with a higher TC variability had a higher incidence of progression of kidney function decline compared to those with a lower variability in TC. However, well-designed prospective studies are required to further clarify the link between cholesterol variability and renal function decline and to determine the mechanisms accounting for this association. Also, further studies are badly needed to figure out how to measure cholesterol variability and the accepted "normal" value for cholesterol variability.
